Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

73.39 -0.11 (-0.15%)
Streaming Delayed Price Updated: 11:46 AM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,266,517
Open 74.00
Bid (Size) 73.38 (6)
Ask (Size) 73.39 (3)
Prev. Close 73.50
Today's Range 72.88 - 74.01
52wk Range 62.75 - 87.67
Shares Outstanding N/A
Dividend Yield 1.36%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Approves AstraZeneca's Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients
FDA approved AstraZeneca's Imfinzi regimen for muscle-invasive bladder cancer, while the EU backed Calquence combo for untreated mantle cell lymphoma. 
Via Benzinga
Exposures Product Safety
Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?
The company unveiled promising results for its experimental cholesterol treatment, a daily pill that blocks PCSK9. 
Via Investor's Business Daily

Performance

YTD
+11.4%
+11.4%
1 Month
-3.6%
-3.6%
3 Month
+11.9%
+11.9%
6 Month
-5.8%
-5.8%
1 Year
+9.1%
+9.1%

More News

Read More
​​AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial
From AstraZeneca
Via Business Wire
IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
From AstraZeneca
Via Business Wire
Competitive Analysis In The ATTR-CM Field
Via Talk Markets
Topics Stocks / Equities
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug
Via Benzinga
Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements
Via FinancialNewsMedia
J&J Drug Combo Outperforms Leading Lung Cancer Treatment In Survival Study
Via Benzinga
New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings
From AstraZeneca
Via Business Wire
Forget the Correction: This Stock Is Defying the Sell-Off, and There Might Be More Upside Ahead
Via The Motley Fool
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
Via Benzinga
Two Sectors Just Tried And Failed - And That’s Great For Us
Via Talk Markets
Topics Stocks / Equities
A Potential Challenger For AstraZeneca's Blockbuster Lung Cancer Drug?
Via Benzinga
Eventful Monday For AstraZeneca - What's Going On?
Via Benzinga
AstraZeneca Seals Deal For EsoBiotec To Advance Cell Therapy: Details
Via Benzinga
AstraZeneca and Erin Andrews team up to inspire fans to Get Body Checked Against Cancer
From AstraZeneca
Via Business Wire
Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst
Via Benzinga
EXCLUSIVE: Vivani Medical Announces First Implant In Early-Stage Human Study Of GLP-1 Implant For Obesity
Via Benzinga
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion
Via Investor's Business Daily
Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal
Via Benzinga
One Week Is Currently Like A Decade In These Markets
Via Talk Markets
Topics ETFs Stocks / Equities
Is ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN) suited for quality investing?
Via Chartmill
AstraZeneca's Imfinzi-Based Regimen Shows Improved Event-Free Survival In Early-Stage Gastric Cancer Patients
Via Benzinga
IMFINZI® (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers
From AstraZeneca
Via Business Wire
Kiniksa Pharmaceuticals Stock Is Attractive From Valuation Perspective-JP Morgan Analyst
Via Benzinga

Frequently Asked Questions

Is AstraZeneca PLC - American Depositary Shares publicly traded?
Yes, AstraZeneca PLC - American Depositary Shares is publicly traded.
What exchange does AstraZeneca PLC - American Depositary Shares trade on?
AstraZeneca PLC - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for AstraZeneca PLC - American Depositary Shares?
The ticker symbol for AstraZeneca PLC - American Depositary Shares is AZN on the Nasdaq Stock Market
What is the current price of AstraZeneca PLC - American Depositary Shares?
The current price of AstraZeneca PLC - American Depositary Shares is 73.39
When was AstraZeneca PLC - American Depositary Shares last traded?
The last trade of AstraZeneca PLC - American Depositary Shares was at 04/01/25 11:46 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.